Global S&T Development Trend Analysis Platform of Resources and Environment
Government-funded Imperial College COVID-19 vaccine moves into first human trials | |
admin | |
2020-06-15 | |
发布年 | 2020 |
语种 | 英语 |
国家 | 英国 |
领域 | 气候变化 ; 资源环境 |
正文(英文) |
Press release
Government-funded Imperial College COVID-19 vaccine moves into first human trialsClinical researchers will begin human trials of a new coronavirus vaccine developed by researchers at Imperial College London. ![]() Clinical researchers will begin human trials of a new coronavirus vaccine developed by researchers at Imperial College London. Beginning this week, the study will be the first time the vaccine has been trialled in humans and will test whether it is well-tolerated and produces an effective immune response against COVID-19. This latest milestone follows £41 million in government funding towards the development of Imperial College London’s vaccine. A further £5 million of philanthropic gifts, including from hundreds of members of the public, has accelerated the work. The trials will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases. The vaccine has undergone rigorous pre-clinical safety tests and has been shown to be safe and produced encouraging signs of an effective immune response in animal studies. Over the coming weeks, 300 healthy participants will receive two doses of the vaccine. Many traditional vaccines are based on a weakened or modified form of virus, or parts of it, but the Imperial vaccine is based on a new approach. It uses synthetic strands of genetic code (called RNA), based on the virus’s genetic material. If the vaccine shows a promising immune response, then larger Phase III trials would be planned to begin later in the year with around 6000 healthy volunteers to test its effectiveness. Ultimately, the researchers hope that if clinical trials are successful, the vaccine could provide protection against COVID-19 both in the UK and around the world. Professor Robin Shattock, from the Department of Infectious Disease at Imperial and who is leading the work, said:
Business Secretary, Alok Sharma, said:
Kate Bingham, Vaccine Taskforce Chair, said:
Notes to editorsKey points:
Published 15 June 2020
|
URL | 查看原文 |
来源平台 | Department for Business, Energy & Industrial Strategy |
文献类型 | 新闻 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/274624 |
专题 | 气候变化 资源环境科学 |
推荐引用方式 GB/T 7714 | admin. Government-funded Imperial College COVID-19 vaccine moves into first human trials. 2020. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
查看访问统计 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[admin]的文章 |
百度学术 |
百度学术中相似的文章 |
[admin]的文章 |
必应学术 |
必应学术中相似的文章 |
[admin]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论